Markets:

Overview

News

Currencies

International

Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

11.87 +0.25 (+2.15%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? ↗

November 21, 2021

CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations.

Via The Motley Fool

Novartis Has $21B From Roche Stake Sale - Which Company Is On Its M&A Radar? ↗

November 18, 2021

Novartis AG (NYSE: NVS) is getting a massive influx of cash from selling its 20-year stake in Roche Holdings AG (OTC: RHHBY), triggering speculation...

Via Benzinga

Looking for Growth in Small and Mid Cap Life Science Stocks ↗

November 15, 2021

2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps.

Via Talk Markets

Intellia Therapeutics, Inc (NTLA) Q3 2021 Earnings Call Transcript ↗

November 06, 2021

NTLA earnings call for the period ending October 3, 2021.

Via The Motley Fool

Topics Earnings

Intellia Therapeutics & UiPath Elliott Wave Analysis ↗

October 09, 2021

US Stocks NTLA &PATH technical analysis, Elliott Wave forecast & trading.

Via Talk Markets

Stock Trading: Intellia Therapeutics Inc & Zillow Technical Analysis ↗

October 02, 2021

Intellia and Zillow technical analysis, Elliott Wave forecast.

Via Talk Markets

Where Intellia Therapeutics Stands With Analysts ↗

September 24, 2021

Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed t...

Via Benzinga

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

EVP And Chief Medical Officer Of Intellia Therapeutics Trades $340K In Company Stock ↗

October 18, 2021

David Lebwohl, EVP And Chief Medical Officer at Intellia Therapeutics (NASDAQ:NTLA), made a large buy and sell of company shares on October 14, according to a new SEC filing. What...

Via Benzinga

Topics Regulatory Compliance

Technical Analysis : Pinduoduo (PINS) & Intellia Therapeutics (NTLA) ↗

September 01, 2021

Here's a technical analysis of two stocks: Pinduoduo (PDD) & Intellia Therapeutics.

Via Talk Markets

CareDx & Intellia Therapeutics Elliott Wave Analysis ↗

August 25, 2021

At this point the flat correction into wave (4) could be completed, if not we are just missing one last leg down.

Via Talk Markets

Where Intellia Therapeutics Stands With Analysts ↗

August 06, 2021

Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst rati...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

2 Gene-Editing Stocks to Have on Your Radar Right Now ↗

October 17, 2021

They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.

Via The Motley Fool

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week ↗

October 15, 2021

A key gene-editing readout had Cathie Wood shuffling her portfolio.

Via The Motley Fool

The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal ↗

October 13, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the...

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 08, 2021

Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6...

Via Benzinga

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs ↗

October 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)...

Via Benzinga

Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients ↗

October 06, 2021

The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) Phase 1/2 study of NTLA-2002...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2021 ↗

October 05, 2021

Upgrades Wolfe Research upgraded the previous rating for PACCAR Inc (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021 ↗

September 24, 2021

Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ:

Via Benzinga

Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients ↗

September 16, 2021

The FDA has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) investigational new drug (IND) application for NTLA-5001. Related Content: Intellia...

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 16, 2021

Gainers Leap Therapeutics (NASDAQ:LPTX) stock rose 32.64% to $2.56 during Thursday's pre-market session. The company's market cap stands at $152.7 million. Phio...

Via Benzinga

Forget About the Genomic Revolution, the Proteomic Revolution Is Coming ↗

September 03, 2021

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing.

Via InvestorPlace

Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today ↗

August 23, 2021

Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology.

Via InvestorPlace

US Stocks: AME, AVAV, NIO, NTLA, PDD & SNAP Technical Analysis ↗

August 09, 2021

Technical stocks analysis: Ametek, AeroVironment, Nio Inc, Intellia Therapeutics, Pinduoduo, and Snap.

Via Talk Markets

Intellia Therapeutics, inc (NTLA) Q2 2021 Earnings Call Transcript ↗

August 06, 2021

NTLA earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

10 Biggest Price Target Changes For Friday ↗

August 06, 2021

Piper Sandler boosted the price target for Moderna, Inc. (NASDAQ: MRNA) from $246 to $445. Moderna shares fell 1.6% to $409.55 in pre-market trading. Needham cut the price...

Via Benzinga

99 Biggest Movers From Yesterday ↗

August 06, 2021

Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...

Via Benzinga

Why Shares of Intellia Therapeutics Are Jumping Today ↗

August 05, 2021

More progress in the pipeline has investors bullish on the company's shares.

Via The Motley Fool

< Previous 1 2

...

14 15 16 17 18 19 20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

All News about Intellia Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today